Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann Johnson

Showing results (341-350 of 349) with videos related to

Pageof 35
Sort By:
You have reached the last page of results.This site can display upto 349 results.
Cell|June 6, 2022
Potent cross-reactive antibodies following Omicron breakthrough in vaccineesRungtiwa Nutalai, Daming Zhou, Aekkachai Tuekprakhon, et al.
The Lancet. Oncology|December 16, 2019
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trialsAlexander Drilon, Salvatore Siena, Rafal Dziadziuszko, et al.
Cell Reports|December 31, 2022
A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75Jiandong Huo, Aiste Dijokaite-Guraliuc, Chang Liu, et al.
The Lancet. Oncology|December 16, 2019
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trialsRobert C Doebele, Alexander Drilon, Luis Paz-Ares, et al.
JAMA|December 9, 2025
Expectant Management vs Medication for Patent Ductus Arteriosus in Preterm Infants: The PDA Randomized Clinical TrialMatthew M Laughon, Sonia M Thomas, Kristi L Watterberg, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|April 27, 2026
Total versus subtotal gastrectomy following neoadjuvant flot chemotherapy for distal diffuse gastric adenocarcinoma: an international cohort studyJonathan Sivakumar, Darren J Wong, Katheryn Hall, et al.
Cell|July 9, 2021
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serumChang Liu, Helen M Ginn, Wanwisa Dejnirattisai, et al.
Biorxiv : the Preprint Server for Biology|January 4, 2022
Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responsesWanwisa Dejnirattisai, Jiandong Huo, Daming Zhou, et al.
Cell|January 26, 2022
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responsesWanwisa Dejnirattisai, Jiandong Huo, Daming Zhou, et al.
Pageof 35

Showing results (341-350 of 349) with videos related to

Sort By:
Pageof 35
You have reached the last page of results.This site can display upto 349 results.
Cell|June 6, 2022
Potent cross-reactive antibodies following Omicron breakthrough in vaccineesRungtiwa Nutalai, Daming Zhou, Aekkachai Tuekprakhon, et al.
The Lancet. Oncology|December 16, 2019
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trialsAlexander Drilon, Salvatore Siena, Rafal Dziadziuszko, et al.
Cell Reports|December 31, 2022
A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75Jiandong Huo, Aiste Dijokaite-Guraliuc, Chang Liu, et al.
The Lancet. Oncology|December 16, 2019
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trialsRobert C Doebele, Alexander Drilon, Luis Paz-Ares, et al.
JAMA|December 9, 2025
Expectant Management vs Medication for Patent Ductus Arteriosus in Preterm Infants: The PDA Randomized Clinical TrialMatthew M Laughon, Sonia M Thomas, Kristi L Watterberg, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|April 27, 2026
Total versus subtotal gastrectomy following neoadjuvant flot chemotherapy for distal diffuse gastric adenocarcinoma: an international cohort studyJonathan Sivakumar, Darren J Wong, Katheryn Hall, et al.
Cell|July 9, 2021
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serumChang Liu, Helen M Ginn, Wanwisa Dejnirattisai, et al.
Biorxiv : the Preprint Server for Biology|January 4, 2022
Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responsesWanwisa Dejnirattisai, Jiandong Huo, Daming Zhou, et al.
Cell|January 26, 2022
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responsesWanwisa Dejnirattisai, Jiandong Huo, Daming Zhou, et al.
Pageof 35